Breo Ellipta 50 ug/1 (Fluticasone Furoate and Vilanterol Trifenatate POWDER) 50 ug/1

Breo Ellipta 50 ug/1 is a combination inhaler containing fluticasone furoate and vilanterol trifenatate. It is designed for respiratory use and is commonly used for managing asthma and chronic obstructive pulmonary disease (COPD). This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Strength

50 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0916-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Breo Ellipta 50 ug/1 is primarily used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The inhaler combines two active ingredients: fluticasone furoate, a corticosteroid, and vilanterol trifenatate, a long-acting beta-agonist. These components work together to reduce inflammation and relax the muscles in the airways, making it easier to breathe. People often ask, 'What is Breo Ellipta used for?' and the answer is that it is typically prescribed for long-term management of these respiratory conditions.

Side Effects

Common effects of using Breo Ellipta 50 ug/1 may include a reduction in airway inflammation and improved breathing. Some users might experience side effects such as headache, throat irritation, or a dry mouth. It is important to note that individual responses can vary, and not everyone will experience these effects. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Breo Ellipta 50 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions carefully. The inhaler should be stored at room temperature and kept out of reach of children. Users should be aware of potential side effects and seek medical advice if they experience any severe or persistent symptoms.

Avoid Interactions

Breo Ellipta 50 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is also important to avoid using other long-acting beta-agonists while using this inhaler. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare provider to avoid potential interactions.

Frequently Asked Questions

Breo Ellipta is used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Breo Ellipta 50 ug/1 should be used as directed by a healthcare professional. Follow the prescribed dosage and administration instructions carefully.

Common side effects may include headache, throat irritation, or a dry mouth. Individual responses can vary.

Breo Ellipta may interact with other medications, including beta-blockers and diuretics. Consult a healthcare provider for personalized advice.

Breo Ellipta should be stored at room temperature and kept out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.